ACTA1 and metabolic dysfunction-associated steatohepatitis: Furthermore, patients with CC seem to have a more aggressive disease than those with NASH cirrhosis, as indicated by greater hepatic collagen content and α‐SMA expression on biopsy, higher serum fibrosis markers and MELD scores and a greater risk of liver‐related clinical events during follow‐up.51